Nodular ganglioneuroblastoma

Summary

Nodular ganglioneuroblastoma (MONDO:0003325) is a disease and 4 clinical trials. Top therapeutic interventions include dexrazoxane, dinutuximab, and isotretinoin. A subtype of ganglioneuroblastoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nodular ganglioneuroblastoma
Mondo ID	MONDO:0003325
DOID	DOID:5193
NCIT	C42058
UMLS	C1517445
MedGen	309203
GARD	0023449
Is cancer (heuristic)	no

Also known as: ganglioneuroblastoma, nodular

Disease family

This is a subtype of ganglioneuroblastoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › embryonal neoplasm › primitive neuroectodermal tumor › neuroblastic tumor › ganglioneuroblastoma › nodular ganglioneuroblastoma

Related subtypes (2): intermixed schwannian stroma-rich ganglioneuroblastoma, peripheral ganglioneuroblastoma

Subtypes (2): stroma-dominant and stroma-poor composite ganglioneuroblastoma, schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03126916	PHASE3	RECRUITING	Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NCT06172296	PHASE3	RECRUITING	Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT04385277	PHASE2	ACTIVE_NOT_RECRUITING	Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
NCT06858501	PHASE2	NOT_YET_RECRUITING	Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXRAZOXANE	4	3
DINUTUXIMAB	4	3
ISOTRETINOIN	4	3
MELPHALAN	4	3
TOPOTECAN	4	3
CISPLATIN	4	2
THIOTEPA	4	2
BUSULFAN	4	1
ETOPOSIDE PHOSPHATE	4	1
IOBENGUANE I 131	4	1
LORLATINIB	4	1
SARGRAMOSTIM	4	1
TEMOZOLOMIDE	4	1
FLORBENGUANE F18	3	1
IOBENGUANE I 123	1	2
CHEMBL4303155	0	1
CHEMBL4436406	0	1
CHEMBL5289235	0	1
CHEMBL4228794	0	1
CHEMBL4248195	0	1